GRANULES · Pharma & Healthcare · small cap · Smallcap 50
What the business sold
What it kept after tax
Profit from operations
Cash the operations produced
Borrowings against the business
Paid out per share · not collected yet
Price index · Start = 100 · Dividends excluded · ₹909.3 today (+1.12%)
As of 13 Sept 2026
Price to book 4.4
Trailing twelve months
Closing prices
| Reported metric | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | 4,496 | 4,490 | 4,456 | 5,339 |
| Operating profit | 738 | 660 | 729 | 901 |
| Net profit | 517 | 405 | 502 | 595 |
| Operating cash flow | 739 | 439 | 867 | 793 |
| Free cash flow | 328 | 59 | 295 | 235 |
| Capital expenditure | -411 | -381 | -572 | -558 |
| Tax expense | 171 | 142 | 159 | 190 |
| Total debt | 1,136 | 1,315 | 1,455 | 1,512 |
| Cash and equivalents | 292 | 381 | 466 | 880 |
| Shareholders equity | 2,835 | 3,226 | 3,716 | 5,085 |
| Earnings per share (₹) | 21.00 | 16.72 | 20.68 | 24.46 |
Not collected yet for this company: Dividend per share. These come from the filings, not the daily price feed.
| Quarter ended | Revenue | Operating profit | Net profit | EPS (₹) |
|---|---|---|---|---|
| 30 Jun 2026 | 1,465 | 259 | 180 | 7.12 |
| 31 Mar 2026 | 1,457 | 270 | 202 | 8.23 |
| 31 Dec 2025 | 1,378 | 235 | 150 | 6.19 |
| 30 Sept 2025 | 1,295 | 206 | 131 | 5.38 |
| 30 Jun 2025 | 1,209 | 178 | 113 | 4.64 |
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
Names an event that should show up in revenue, profit, debt, capacity or approvals.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
Names an event that should show up in revenue, profit, debt, capacity or approvals.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
Names an event that should show up in revenue, profit, debt, capacity or approvals.
Classifier confidence: 0.35. This is not the probability that the report is true.
The headline states a business fact and a direction that hurts it. This classifies the headline only, not the full article. It is not a recommendation.
Names an event that should show up in revenue, profit, debt, capacity or approvals.
Classifier confidence: 0.60. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
Names an event that should show up in revenue, profit, debt, capacity or approvals.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
Names an event that should show up in revenue, profit, debt, capacity or approvals.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
Names an event that should show up in revenue, profit, debt, capacity or approvals.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.
Classifier confidence: 0.35. This is not the probability that the report is true.
The headline states a business fact and a direction that hurts it. This classifies the headline only, not the full article. It is not a recommendation.
Names an event that should show up in revenue, profit, debt, capacity or approvals.
Classifier confidence: 0.60. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
Somebody's reading of events rather than an event. Worth the argument; not a filing.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
Somebody's reading of events rather than an event. Worth the argument; not a filing.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.
Classifier confidence: 0.35. This is not the probability that the report is true.
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), finished dosages (FDs), and peptides CDMO in India and internationally. It offers paracetamol, metformin, guaifenesin, ibuprofen, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for oral solutions. In addition, it provides development and manufacturing solutions for peptides, peptide fragments, and amino acid derivatives. The company offers its products in various therapeutic categories, including antiretroviral, anti-depressant, antihistamine, anti-diabetic, anti-cancer, multiple sclerosis, anti-thrombocytopenia, anti-ulcer, anti-convulsant, mucolytic/expectorant, anti-hypertensive, muscle relaxant, NSAIDs, anti-fibrotic, and anti-microbial, as well as anti-arrhythmic, CNS stimulant, anti-diarrheal, antihypertensive, uterine stimulant, chelating agent, mineral supplements, CNS depressant, PDE inhibitor, antispasmodic, and anti-viral. Granules India Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Industry: Drug Manufacturers - Specialty & Generic
Prices, fundamentals and developments last verified 13 Sept 2026. Fundamentals are sourced from public filings feeds; interpretation is shown separately from figures.
Guests see a sample. Members get every company, five-year fundamentals, classified developments, a watchlist and the decision journal.
Sign in with Google